• Majed Alshamrani, Atika AlHarbi, Nora Alkhudair, Fouad AlNajjar, Mansoor Khan, Abdulaziz Ben Obaid, Amr Khardaly, Eshtyag Bajnaid, Hadeel Samarkandi, Aeshah AlAzmi, Salman Alabdali, and Mohammed AlNahedh.
• Saudi Oncology Pharmacy Assembly, Riyadh, Saudi Arabia.
• J Oncol Pharm Pract. 2020 Sep 1; 26 (6): 1429-1440.

PurposeDuring COVID-19 pandemic, cancer patients are considered one of the most vulnerable to infection since they tend to have advanced age, multiple comorbidities, and are often immunosuppressed by their cancer or therapy. Hence, the Saudi Oncology Pharmacy Assembly has issued recommendations to reduce the frequency of cancer patients' visits to oncology centers during the pandemic while maintaining the access to cancer therapy and minimize the risk of exposure to coronavirus disease.Materials And MethodsA qualitative methodological approach was conducted in April 2020 using a virtual panel discussion for collection of recommendations.ResultsA total of 12 expert oncology pharmacy practitioners shared their knowledge and experiences in managing oncology patients during the COVID-19 pandemic. The participants recognized many fundamental recommendations that were already applied in many cancer centers since the start of the COVID-19 outbreak. On that basis, the panelists developed eight practice-related recommendations for action, with a main focus on cancer treatment modification.ConclusionsIn conclusion, delivering cancer care during the COVID-19 pandemic carries significant challenges. This paper addressed suggestions to properly manage cancer patients during difficult times. Implementing changes in practice mandates a national collaborative effort from different sectors to guarantee the quality and continuity of care. The SOPA expert panel developed these recommendations, to ultimately contribute in maintaining access to cancer therapy while minimizing the risk of COVID-19 exposure.

19 keywords...

hide…